April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
January 2015 in “Вестник дерматологии и венерологии” Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The treatment effectively promoted hair growth with minimal side effects.
July 2011 in “Springer eBooks” The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
Combining platelet-rich plasma with other treatments may improve hair growth in androgenetic alopecia.
Combining platelet-rich plasma with other treatments may improve hair growth in androgenetic alopecia.
May 2026 in “Skin Appendage Disorders” Combining PRP with other treatments may improve hair growth more than PRP alone.
March 2026 in “Lithuanian University of Health Sciences” Finasteride, dutasteride, and oral minoxidil are effective for treating hair loss, with spironolactone as an option for women.
Early combination therapy can effectively regrow hair in frontal fibrosing alopecia.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Dermatologic Surgery” Injectable therapy, especially with dutasteride, may help with hair loss, but more research is needed.
January 2026 in “Ciencia Latina Revista Científica Multidisciplinar” Exosome-based therapy successfully restored hair in a 14-year-old with difficult-to-treat alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
January 2026 in “Ciencia Latina Revista Científica Multidisciplinar” Exosomes helped regrow hair in a 14-year-old with difficult-to-treat alopecia.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
January 2026 in “International Society of Hair Restoration Surgery” Tattoo machine-assisted drug delivery may improve hair growth in androgenetic alopecia.